RVL Pharma’s Units File Bankruptcy, Shares to Be Canceled (1)

RVL Pharmaceuticals Plc, a drug maker focusing on a pharmaceutical to treat droopy eyelid in adults, placed some of its US units into bankruptcy and plans to wind down other operations, citing strained liquidity and negative industry trends.

Three of its units — RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals Inc. and RVL Pharmacy LLC — filed for Chapter 11 bankruptcy protection in Delaware on Thursday with a plan to hand control to lender Athyrium Capital Management in a prepackaged bankruptcy, according to a statement.RevitaLid listed assets and liabilities of at least $100 million each in its court petition. ...